[ Price : $8.95]
FDA removes a clinical hold against Intellia Therapeutics and its MAGNITUDE Phase 3 trial of nexiguran ziclumeran (nex-z), an expe...[ Price : $8.95]
Three former senior FDA officials tell a federal appeals court that the Trump administration mischaracterized the science on contr...[ Price : $8.95]
HHS directs FDA and other health agency employees to immediately stop using the artificial intelligence platform Claude after the ...[ Price : $8.95]
FDA approves a Synergy Spine Solutions PMA for its Synergy Disc, a motion-preserving artificial cervical disc.[ Price : $8.95]
A leading myeloma researcher says FDAs draft guidance endorsing minimal residual disease as a potential basis for accelerated drug...[ Price : $8.95]
Drug user fee negotiators confront lingering divisions over FDAs America First proposals and the structure of hiring commitments, ...[ Price : $8.95]
The U.S. Department of Justice (DoJ) says a Federal Circuit ruling on so-called generic drug skinny labels threatens to undermine ...[ Price : $8.95]
Rare disease drug developers and patient advocates are applauding a series of new guidance documents from FDA that bring long-awai...